絞り込み

18454

広告

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.

著者 Wei AH , Strickland SA , Hou JZ , Fiedler W , Lin TL , Walter RB , Enjeti A , Tiong IS , Savona M , Lee S , Chyla B , Popovic R , Salem AH , Agarwal S , Xu T , Fakouhi KM , Humerickhouse R , Hong WJ , Hayslip J , Roboz GJ
J Clin Oncol.2019 Mar 20 ; ():JCO1801600.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (24view , 0users)

Full Text Sources

Medical

Effective treatment options are limited for patients with acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. An international phase Ib/II study evaluated the safety and preliminary efficacy of venetoclax, a selective B-cell leukemia/lymphoma-2 inhibitor, together with low-dose cytarabine (LDAC) in older adults with AML.
PMID: 30892988 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード